Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. STX-478 could represent the ...

Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies.